Pharmaceuticals News and Research

RSS

Biphasic insulin provides significant improvements in more than 52,000 diabetic patients

A major international diabetes study of more than 52,000 patients from eight countries has shown that using biphasic BIAsp 30 insulin resulted in significant clinical improvements and greater patient satisfaction.

2 Mar 2009

Endo Pharmaceuticals licenses investigational drug axomadol from Grunenthal

Endo Pharmaceuticals announced that it has licensed from Grunenthal the exclusive rights to develop and market the investigational drug axomadol in the United States and Canada.

2 Mar 2009

ESA Biosciences to launch Corona CAD at Pittcon 2009

ESA Biosciences, Inc., a Magellan Biosciences company and leader in novel HPLC systems that improve results for pharmaceutical development and QA/QC, life science, and analytical-chemistry customers worldwide, will launch a new, ultra-high-performance version of its award-winning Corona CAD at Pittcon 2009.

2 Mar 2009

FDA takes action against KV Pharmaceutical Company

The FDA announced a Consent Decree of permanent injunction filed March 2, 2009, enjoining KV Pharmaceutical Company, its subsidiaries ETHEX Corporation and Ther-Rx Corporation, and its principal officers from making and distributing adulterated and unapproved drugs.

2 Mar 2009

Epstein-Barr virus may be associated with progression of multiple sclerosis

Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neurodegeneration that occurs in persons with multiple sclerosis, researchers at the University at Buffalo and the University of Trieste, Italy, have shown.

2 Mar 2009

Antibody recognition of a highly conserved epitope across influenza viruses

The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.

26 Feb 2009

Research points to new antiviral drugs and universal influenza vaccines

WHAT: Researchers at The Scripps Research Institute in La Jolla, California, supported in part by the National Institutes of Health, have identified a common Achilles' heel in a wide range of seasonal and pandemic influenza A viruses.

26 Feb 2009

Experimental animal vaccine may protect humans from Ebola

Protection against Ebola, one of the world's deadliest viruses, can be achieved by a vaccine produced in insect cells, raising prospects for developing an effective vaccine for humans, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

26 Feb 2009

Zoologists search sea for drugs of the future

No matter how sophisticated modern medicine becomes, common ailments like fungal infections can outrun the best of the world's antibiotics.

26 Feb 2009

VIA Pharmaceuticals awarded new patent on lead compound VIA-2291

VIA Pharmaceuticals, Inc. has announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of atherosclerosis.

25 Feb 2009

United States files complaint against Forest Labs for allegedly violating the false claims act with Celexa and Lexapro

A Complaint was unsealed today in U.S. District Court in Massachusetts against a New York pharmaceutical company for alleged False Claims Act violations arising from the company's marketing the drugs Celexa and Lexapro for unapproved pediatric use and for paying kickbacks to induce physicians to prescribe the drugs.

25 Feb 2009

Two compounds show great promise for cerebral palsy

Two compounds developed by Northwestern University chemists have been shown to be effective in pre-clinical trials in protecting against cerebral palsy, a condition caused by neurodegeneration that affects body movement and muscle coordination.

25 Feb 2009

Parents learn about human papillomavirus vaccine mostly from pharmaceutical advertising

Parents and other caretakers of young women learned about human papillomavirus (HPV) vaccine primarily from advertisements sponsored by the pharmaceutical company that makes the vaccine, a new study from the University of North Carolina at Chapel Hill shows.

25 Feb 2009

Mylan's Matrix receives WHO approval for generic Lopinavir/Ritonavir tablets

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received the first and only World Health Organization (WHO) approval for Lopinavir/Ritonavir Tablets, 200 mg/50 mg. Matrix's version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.

25 Feb 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

Shire to enter European ADHD market with acquisition of EQUASYM IR and XL

Shire plc has announced that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

22 Feb 2009

Scientists mine drugs database for new diabetes treatment

Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.

22 Feb 2009

Endo and Penwest announce settlement of Opana ER litigation

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Actavis South Atlantic LLC regarding the production and sale of generic formulations of Opana(R) ER (oxymorphone hydrochloride) Extended Release Tablets CII.

22 Feb 2009

Questions of ethics and quality cloud globalization of clinical trials

Top-tier U.S.-based pharmaceutical companies are moving their clinical trials overseas at warp speed, raising questions about ethics, quality control, and even the scientific value of their findings for people back in the U.S.

20 Feb 2009